Arietis Pharma

Arietis Pharma is a private, preclinical-stage biotech developing a novel class of antibiotics that activate the ClpP protease, causing bacterial cells to self-digest. This unique mechanism offers rapid killing of drug-resistant Gram-positive pathogens, including MRSA and VRE, and is effective against non-growing cells and biofilms where traditional antibiotics fail. Founded on technology from Northeastern University's Antimicrobial Discovery Center, the company aims to treat complicated infections like prosthetic joint infections and endocarditis. Its strategy includes combining ClpP activators with traditional antibiotics to prevent resistance and eradicate persistent infections.

Platform for discovering small molecule activators of the bacterial ClpP protease, a conserved enzyme that, when aberrantly activated, causes uncontrolled proteolysis and bacterial cell death. This mechanism is effective against dormant persister cells and biofilms.

The competitive landscape includes other biotechs and academia pursuing ClpP activators, as well as companies developing alternative non-traditional antimicrobials (e.g., lysins, antibodies, virulence inhibitors). Arietis differentiates itself with its foundational IP and extensive preclinical validation from the Lewis lab, specifically targeting the persistent cell problem.